In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

about

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

P2860

Q47901866-183FEC85-34AF-41F1-9322-48386F58526E Q48223561-42BC101A-B3CC-46E2-A167-6F715C3C5C3C

P2860

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

Item

http://www.wikidata.org/entity/Q48004908

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@en

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@nl

type

Item

label

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@en

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@nl

prefLabel

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@en

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@nl

P1476

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

@en

P2093

David J Greenblatt

http://www.w3.org/2001/XMLSchema#string

Md Amin Hossain

http://www.w3.org/2001/XMLSchema#string

Novera Alam

http://www.w3.org/2001/XMLSchema#string

Sara Algeelani

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.

The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.

Pharmacokinetic enhancers in HIV therapeutics.

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

Mechanisms and Consequences of Drug-Drug Interactions.

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00498254.2017.1370655

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Gerd Mikus

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28891378

http://www.w3.org/2001/XMLSchema#string

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

about

P2860

P2860

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698